Risk factors of breakthrough aspergillosis in lung transplant recipients receiving itraconazole prophylaxis

Invasive Aspergillus infection (IA) in lung transplantation can result in poor outcomes. Itraconazole has been shown to be effective for fungal prophylaxis in lung transplant recipients. However, IA remains a major cause of death after lung transplantation. Therefore, we aimed to clarify the risk fa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022-01, Vol.28 (1), p.54-60
Hauptverfasser: Katada, Yoshiki, Nakagawa, Shunsaku, Nagao, Miki, Yoshida, Yuko, Matsuda, Yuya, Yamamoto, Yuki, Itohara, Kotaro, Imai, Satoshi, Yonezawa, Atsushi, Nakagawa, Takayuki, Matsubara, Kazuo, Tanaka, Satona, Nakajima, Daisuke, Date, Hiroshi, Terada, Tomohiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Invasive Aspergillus infection (IA) in lung transplantation can result in poor outcomes. Itraconazole has been shown to be effective for fungal prophylaxis in lung transplant recipients. However, IA remains a major cause of death after lung transplantation. Therefore, we aimed to clarify the risk factors for IA on itraconazole prophylaxis. We examined 120 recipients to uncover their IA epidemiology, clinical characteristics, and outcomes. In addition, a case-control study was performed to identify risk factors of IA. Of the 120 patients, 12 developed IA under itraconazole prophylaxis. The patient demographics and clinical characteristics were compared among the following two groups: IA group, 12 patients, and control group, 108 patients. Significant differences were observed in age (p = 0.004), history of interstitial pneumonia (p = 0.032), and CMV infection (p 
ISSN:1341-321X
1437-7780
DOI:10.1016/j.jiac.2021.09.020